Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD40 Pan-CoV
- Development stage
- Phase 2
- Lead developer
- EnnoDC
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
CD40 Pan-CoV (also known as EDC.Pan.CoV or CD40.Pan.CoV) is a broad-spectrum recombinant fusion protein vaccine candidate designed to protect against SARS-CoV-2 and related coronaviruses. Developed by the Vaccine Research Institute (VRI) and EnnoDC (formerly LinKinVax), the vaccine consists of a monoclonal antibody targeting the CD40 receptor on dendritic cells, fused to the receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein. By directly targeting and activating dendritic cells through CD40 engagement, the vaccine aims to induce potent and broad-spectrum B and T cell immune responses. It is currently being evaluated in Phase 1/2a clinical trials as a booster injection, administered subcutaneously with or without the adjuvant Hiltonol (poly-ICLC).
- Other names
- CD40 Pan-CoVCD-40 Pan-CoVCD 40 Pan-CoV
02
Targets
CD40 (Cluster of differentiation 40 receptor)SARS-CoV-2 spike
Beyond the preview
Go deeper on CD40 Pan-CoV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD40 Pan-CoV.